Program
CM512
A development code. Also written as “CM512 injection”.
Its studies are mostly in Rhinosinusitis · Dermatitis, Atopic · Rhinitis, Allergic, Perennial · Chronic Urticaria · Asthma, led by Keymed Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciences | 108 open or running | phase 3since Sep 2, 2026 | Aug 11, 2024 | Jul 21, 2027phase 2 · NCT07011524 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 11, 2024First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06553209 · 110 enrolled · China
- Apr 9, 20252 phase 2 studiesNCT06930612, NCT06947980
- May 12, 2025Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT06980142 · 204 planned
- Jun 5, 2025Phase 2 study in AsthmaNCT07011524 · 200 planned · China
- Sep 3, 2025Phase 2 study in Chronic UrticariaNCT07166211 · 48 planned · China
- Nov 13, 2025Phase 2 study in Dermatitis, AtopicNCT07230483 · 246 planned · China
- Apr 2, 2026Phase 2 study in Chronic Rhinosinusitis With Nasal PolyposisNCT07519577 · 120 planned · China
- Sep 2, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)Phase 3 reachedNCT07807826 · 240 planned · China
- Oct 16, 2026Phase 2 study in Rhinitis, Allergic, PerennialNCT07890350 · 200 planned · China
Ahead
- Nov 2, 2026Primary completion: phase 2 study in Chronic UrticariaNCT07166211
- Jul 21, 2027Primary completion: phase 2 study in AsthmaNCT07011524
- Nov 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)NCT07807826
- Dec 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07230483
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07890350Rhinitis, Allergic, Perennial · China | 2 | Not yet recruiting | Jun 2028 | 200 |
| NCT07807826Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) · China | 3 | Not yet recruiting | Nov 2027 | 240 |
| NCT07519577Chronic Rhinosinusitis With Nasal Polyposis · China | 2 | Not yet recruiting | May 31, 2028 | 120 |
| NCT07230483Dermatitis, Atopic · China | 2 | Recruiting | Dec 2027 | 246 |
| NCT07166211Chronic Urticaria · China | 2 | Recruiting | Nov 2, 2026 | 48 |
| NCT07011524Asthma · China | 2 | Recruiting | Jul 21, 2027 | 200 |
| NCT06980142Pulmonary Disease, Chronic Obstructive | 2 | Not yet recruiting | Mar 17, 2028 | 204 |
| NCT06947980Dermatitis, Atopic · China | 2 | Recruiting | Jul 18, 2026 | 200 |
| NCT06930612Chronic Rhinosinusitis With Nasal Polyposis · China | 2 | Completed | Apr 20, 2026 | 120 |
| NCT06553209Dermatitis, Atopic · China | 1 | Completed | Aug 26, 2025 | 110 |
How it is read
Names in the registry
- “CM512”, 8 entries
- “CM512 injection”, 2 entries
Codes read as this program: CM512.
Conditions, from the studies’ own filings
- Rhinosinusitis, 3 studies
- Dermatitis, Atopic, 3 studies
- Rhinitis, Allergic, Perennial, 1 study
- Chronic Urticaria, 1 study
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.